(Updated - May 18, 2021 8:01 AM EDT)(correction: rating Neutral, not Buy)Goldman Sachs analyst Chris Shibutani initiates coverage on BioNTech ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE